Antineoplastic chemotherapy of the older cancer patient (Q33841164)

29 July 2017

1 reference

title

Antineoplastic chemotherapy of the older cancer patient (English)

1 reference

29 July 2017

1 reference

1 reference

Balducci L

1

1 reference

29 July 2017

Corcoran MB

series ordinal

2

1 reference

29 July 2017

publication date

1 February 2000

1 reference

Hematology / Oncology Clinics of North America

29 July 2017

published in

1 reference

29 July 2017

volume

14

1 reference

29 July 2017

issue

1

1 reference

29 July 2017

page(s)

193-212, x-xi

1 reference

American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970284-7

7 January 2021

Aggressive Chemotherapy for Diffuse Histiocytic Lymphoma in the Elderly: Increased Complications with Advancing Age

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970284-7

7 January 2021

Pharmacology of cancer chemotherapy in the older person.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970284-7

7 January 2021

Cancer and aging. An evolving panorama

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970284-7

7 January 2021

Systemic treatment of cancer in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970284-7

7 January 2021

Cancer in the frail patient. A coming epidemic

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970284-7

7 January 2021

Hematopoiesis and cytokines. Relevance to cancer and aging

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970284-7

7 January 2021

Elderly patients with aggressive non-Hodgkin's lymphoma: disease presentation, response to treatment, and survival--a Groupe d'Etude des Lymphomes de l'Adulte study on 453 patients older than 69 years

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970284-7

7 January 2021

The treatment of elderly patients with aggressive non-Hodgkin's lymphomas: feasibility and efficacy of an intensive multidrug regimen

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970284-7

7 January 2021

Depressive symptoms and 3-year mortality in older hospitalized medical patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970284-7

7 January 2021

Pharmacokinetic studies in elderly people. Are they necessary?

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970284-7

7 January 2021

Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970284-7

7 January 2021

Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970284-7

7 January 2021

Relation between cognitive impairment and early death in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970284-7

7 January 2021

Acute leukemia in the elderly.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970284-7

7 January 2021

Assessment of the older cancer patient

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970284-7

7 January 2021

Cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in women more than 65 years old with advanced breast cancer: the elimination of age trends in toxicity by using doses based on creatinine clearance

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970284-7

7 January 2021

Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970284-7

7 January 2021

Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970284-7

7 January 2021

Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970284-7

7 January 2021

Prognosis and management strategies of lymphatic neoplasias in the elderly. I. Aggressive non-Hodgkin's lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970284-7

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970284-7

7 January 2021

Importance of functional measures in predicting mortality among older hospitalized patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970284-7

7 January 2021

The definition of anemia in older persons

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970284-7

7 January 2021

Cancer chemotherapy in older adults. A tolerability perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970284-7

7 January 2021

Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970284-7

7 January 2021

Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970284-7

7 January 2021

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970284-7

7 January 2021

Value of different modalities of granulocyte-macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970284-7

7 January 2021

The economics of febrile neutropenia: implications for the use of colony-stimulating factors

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970284-7

7 January 2021

A longitudinal study of functional change and mortality in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970284-7

7 January 2021

The association of intraoperative factors with the development of postoperative delirium.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970284-7

7 January 2021

Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970284-7

7 January 2021

Validation of a multidimensional evaluation scale for use in elderly cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970284-7

7 January 2021

Management of drug therapy in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970284-7

7 January 2021

Predictors of immediate and 6-month outcomes in hospitalized elderly patients. The importance of functional status.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970284-7

7 January 2021

Cancer treatment and age: patient perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970284-7

7 January 2021

In search of an optimal regimen for elderly patients with advanced-stage diffuse large-cell lymphoma: results of a phase II study of P/DOCE chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970284-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970284-7

1 reference

7 January 2021

Erythropoietin addition to granulocyte colony-stimulating factor abrogates life-threatening neutropenia and increases peripheral-blood progenitor-cell mobilization after epirubicin, paclitaxel, and cisplatin combination chemotherapy: results of a ra

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970284-7

7 January 2021

Adaptive control of etoposide administration: impact of interpatient pharmacodynamic variability.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970284-7

7 January 2021

Effect of host age on microenvironmental heterogeneity and efficacy of combined modality therapy in solid tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970284-7

7 January 2021

Risk factors for high-dose cytarabine neurotoxicity: an analysis of a cancer and leukemia group B trial in patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970284-7

7 January 2021

Persistence of cisplatin-induced DNA interstrand crosslinking in peripheral blood mononuclear cells from elderly and young individuals

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970284-7

7 January 2021

Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970284-7

7 January 2021

Recombinant hemopoietic growth factors: comparative hemopoietic response in younger and older subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970284-7

7 January 2021

First-cycle blood counts and subsequent neutropenia, dose reduction, or delay in early-stage breast cancer therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970284-7

7 January 2021

Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970284-7

7 January 2021

Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970284-7

7 January 2021

Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970284-7

7 January 2021

Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970284-7

7 January 2021

Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970284-7

7 January 2021

CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970284-7

7 January 2021

The effect of age and frailty upon acetanilide clearance in man

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970284-7

7 January 2021

Prevalence of co-morbidity and its relationship to treatment among unselected patients with Hodgkin's disease and non-Hodgkin's lymphoma, 1993-1996

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970284-7

7 January 2021

Aging and pharmacology

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970284-7

7 January 2021

Screening for frailty: criteria and predictors of outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970284-7

7 January 2021

Aggressive non-Hodgkin's lymphoma in the elderly: an effective, well-tolerated treatment regimen containing extended-schedule etoposide

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970284-7

7 January 2021

10.1016/S0889-8588(05)70284-7

Identifiers

DOI

1 reference

29 July 2017

1 reference